George E Jaskiw1,2, Dongyan Xu3,4, Mark E Obrenovich5,6,7, Curtis J Donskey4,8. 1. Psychiatry Service 116(A), Veterans Affairs Northeast Ohio Healthcare System (VANEOHS), 10701 East Blvd., Cleveland, OH, 44106, USA. gxj5@case.edu. 2. School of Medicine, Case Western Reserve University, Cleveland, OH, USA. gxj5@case.edu. 3. Psychiatry Service 116(A), Veterans Affairs Northeast Ohio Healthcare System (VANEOHS), 10701 East Blvd., Cleveland, OH, 44106, USA. 4. School of Medicine, Case Western Reserve University, Cleveland, OH, USA. 5. Pathology and Laboratory Medicine Service, VANEOHS, Cleveland, OH, USA. 6. Research Service, VANEOHS, Cleveland, OH, USA. 7. Department of Chemistry, Case Western Reserve University, Cleveland, OH, USA. 8. Geriatric Research, Education and Clinical Center (GRECC), VANEOHS, Cleveland, OH, USA.
Abstract
INTRODUCTION: A rapidly growing body of data documents associations between disease of the brain and small molecules generated by gut-microbiota (GMB). While such metabolites can affect brain function through a variety of mechanisms, the most direct action would be on the central nervous system (CNS) itself. OBJECTIVE: Identify indolic and phenolic GMB-dependent small molecules that reach bioactive concentrations in primate CNS. METHODS: We conducted a PubMed search for metabolomic studies of the primate CNS [brain tissue or cerebrospinal fluid (CSF)] and then selected for phenolic or indolic metabolites that (i) had been quantified, (ii) were GMB-dependent. For each chemical we then conducted a search for studies of bioactivity conducted in vitro in human cells of any kind or in CNS cells from the mouse or rat. RESULTS: 36 metabolites of interests were identified in primate CNS through targeted metabolomics. Quantification was available for 31/36 and in vitro bioactivity for 23/36. The reported CNS range for 8 metabolites 2-(3-hydroxyphenyl)acetic acid, 2-(4-hydroxyphenyl)acetic acid, 3-(3-hydroxyphenyl)propanoic acid, (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid [caffeic acid], 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, 2-acetamido-3-(1H-indol-3-yl)propanoic acid [N-acetyltryptophan], 1H-indol-3-yl hydrogen sulfate [indoxyl-3-sulfate] overlapped with a bioactive concentration. However, the number and quality of relevant studies of CNS neurochemistry as well as of bioactivity were highly limited. Structural isomers, multiple metabolites and potential confounders were inadequately considered. CONCLUSION: The potential direct bioactivity of GMB-derived indolic and phenolic molecules on primate CNS remains largely unknown. The field requires additional strategies to identify and prioritize screening of the most promising small molecules that enter the CNS.
INTRODUCTION: A rapidly growing body of data documents associations between disease of the brain and small molecules generated by gut-microbiota (GMB). While such metabolites can affect brain function through a variety of mechanisms, the most direct action would be on the central nervous system (CNS) itself. OBJECTIVE: Identify indolic and phenolic GMB-dependent small molecules that reach bioactive concentrations in primate CNS. METHODS: We conducted a PubMed search for metabolomic studies of the primate CNS [brain tissue or cerebrospinal fluid (CSF)] and then selected for phenolic or indolic metabolites that (i) had been quantified, (ii) were GMB-dependent. For each chemical we then conducted a search for studies of bioactivity conducted in vitro in human cells of any kind or in CNS cells from the mouse or rat. RESULTS: 36 metabolites of interests were identified in primate CNS through targeted metabolomics. Quantification was available for 31/36 and in vitro bioactivity for 23/36. The reported CNS range for 8 metabolites 2-(3-hydroxyphenyl)acetic acid, 2-(4-hydroxyphenyl)acetic acid, 3-(3-hydroxyphenyl)propanoic acid, (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid [caffeic acid], 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, 2-acetamido-3-(1H-indol-3-yl)propanoic acid [N-acetyltryptophan], 1H-indol-3-yl hydrogen sulfate [indoxyl-3-sulfate] overlapped with a bioactive concentration. However, the number and quality of relevant studies of CNS neurochemistry as well as of bioactivity were highly limited. Structural isomers, multiple metabolites and potential confounders were inadequately considered. CONCLUSION: The potential direct bioactivity of GMB-derived indolic and phenolic molecules on primate CNS remains largely unknown. The field requires additional strategies to identify and prioritize screening of the most promising small molecules that enter the CNS.
Authors: Pavel A Aronov; Frank J-G Luo; Natalie S Plummer; Zhe Quan; Susan Holmes; Thomas H Hostetter; Timothy W Meyer Journal: J Am Soc Nephrol Date: 2011-07-22 Impact factor: 10.121
Authors: S Abhijit; Sunil Jamuna Tripathi; V Bhagya; B S Shankaranarayana Rao; Muthangi V Subramanyam; S Asha Devi Journal: Exp Gerontol Date: 2017-11-22 Impact factor: 4.032
Authors: M L V Azevedo; N B Bonan; G Dias; F Brehm; T M Steiner; W M Souza; A E M Stinghen; F C Barreto; Selene Elifio-Esposito; R Pecoits-Filho; A N Moreno-Amaral Journal: Toxicol Lett Date: 2016-10-17 Impact factor: 4.372
Authors: Lizath M Aguiniga; Wenbin Yang; Ryan E Yaggie; Anthony J Schaeffer; David J Klumpp Journal: Am J Physiol Regul Integr Comp Physiol Date: 2019-04-24 Impact factor: 3.619
Authors: Alexandre Almeida; Alex L Mitchell; Miguel Boland; Samuel C Forster; Gregory B Gloor; Aleksandra Tarkowska; Trevor D Lawley; Robert D Finn Journal: Nature Date: 2019-02-11 Impact factor: 49.962